Lohne

This study evaluates the long-term safety and tolerability of pelacarsen TQJ230 in people with established cardiovascular disease and elevated Lipoproteina who completed a previous related study. It is an open-label extension trial, meaning all participants receive the study drug without placebo comparison. The trial is sponsored by Novartis Pharmaceuticals and focuses on continued treatment after the completion of the parent study. Participants receive monthly injections of pelacarsen 80 mg subcutaneously for up to 36 months during this extension phase. This phase is designed to provide access to the study drug after the initial trial and to monitor participants closely. The study does not involve randomization or blinding, and all enrolled participants receive the active drug. During the study, participants will undergo regular assessments including monitoring for adverse events and cardiovascular events, as well as measuring Lipoproteina levels at baseline and several time points over 36 months. Safety and tolerability will be closely tracked throughout the treatment period. The total duration of participation corresponds to the length of the extension phase, up to three years.

Researchers are evaluating oral minoxidil 1 mg for women with androgenetic alopecia, a type of hormone-related hair loss. This phase III clinical trial aims to compare the effectiveness of oral minoxidil 1 mg to a 2% topical minoxidil solution and placebo, while also monitoring safety. Approximately 520 adult female patients with this condition will participate across multiple centers in Europe. Participants will be randomly assigned to one of three groups oral minoxidil 1 mg once daily plus a topical vehicle solution twice daily an oral placebo once daily plus topical 2% minoxidil solution twice daily or oral placebo once daily plus a topical vehicle solution twice daily. The treatment period lasts six months, with doses taken mainly at home, and includes a screening period and a four-week follow-up. During the 36-week study, patients will visit the clinic five times for examinations and receive two safety phone calls. Assessments include hair photos to measure density, scalp hair growth evaluations, vital signs, blood and urine tests, ECGs, and checks for excessive hair growth. Participants will track daily side effects, medication changes, and pregnancy tests if applicable. The main outcome is the change in hair count in the target scalp area from baseline to week 24.